Revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Veracyte, Inc. (VCYT)
Price$42.53Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $517.1M | $445.8M | $361.1M | $296.5M | $219.5M | $117.5M | $120.4M | $92.0M | $72.0M | $65.1M | $49.5M | $38.2M | $21.9M | $11.6M | $2.6M |
| Gross profit | $362.5M | $298.1M | $229.7M | $175.7M | — | — | $84.3M | $58.9M | $43.8M | $39.6M | $28.0M | $21.6M | $9.3M | $4.0M | −$280,000 |
| Gross margin | 70.10% | 66.88% | 63.62% | 59.24% | — | — | 70.03% | 64.05% | 60.81% | 60.88% | 56.57% | 56.52% | 42.39% | 34.78% | −10.59% |
| Research & development | $70.8M | $69.3M | $57.3M | $40.6M | $29.8M | $17.2M | $14.9M | $14.8M | $13.9M | $15.3M | $12.8M | $9.8M | $7.8M | $6.6M | $6.7M |
| Operating expenses | $304.8M | $282.0M | $446.8M | $337.6M | $301.4M | $152.9M | $135.5M | $114.2M | $98.5M | $93.9M | $83.0M | $67.2M | $45.1M | $30.6M | $17.9M |
| Operating income | $57.8M | $16.1M | −$85.8M | −$41.1M | −$81.9M | −$35.4M | −$15.1M | −$22.2M | −$26.5M | −$28.8M | −$33.5M | −$29.0M | −$23.2M | −$18.9M | −$15.3M |
| Operating margin | 11.17% | 3.62% | −23.76% | −13.85% | −37.31% | −30.12% | −12.57% | −24.16% | −36.88% | −44.25% | −67.60% | −75.95% | −105.89% | −162.79% | −577.16% |
| EBITDA | $79.2M | $39.6M | −$58.6M | −$15.2M | −$62.3M | −$27.4M | −$11.0M | −$18.3M | −$22.7M | −$25.3M | −$31.2M | −$27.8M | −$22.2M | −$18.2M | −$14.7M |
| EBITDA margin | 15.31% | 8.88% | −16.23% | −5.11% | −28.39% | −23.36% | −9.15% | −19.90% | −31.54% | −38.86% | −63.05% | −72.88% | −101.33% | −156.72% | −554.06% |
| Net income | $66.4M | $24.1M | −$74.4M | −$36.6M | −$75.6M | −$34.9M | −$12.6M | −$23.0M | — | — | — | — | — | — | — |
| Net profit margin | 12.83% | 5.41% | −20.61% | −12.33% | −34.42% | −29.71% | −10.47% | −25.00% | — | — | — | — | — | — | — |
| Basic EPSper basic share | $0.84 | $0.32 | -$1.02 | -$0.51 | -$1.11 | -$0.66 | -$0.27 | -$0.62 | -$0.91 | -$1.09 | -$1.30 | -$1.36 | -$6.15 | -$28.68 | -$24.90 |
| Diluted EPSper diluted share | $0.82 | $0.31 | -$1.02 | -$0.51 | -$1.11 | -$0.66 | -$0.27 | -$0.62 | -$0.91 | -$1.09 | -$1.30 | -$1.36 | -$6.15 | -$28.68 | -$24.90 |
Owners
Reported shareholders
16.78%of listed shares
BlackRock, Inc.13.49M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 16.78%13.49M shares |
FMR LLC | 9.58%7.7M shares |
Artisan Partners Limited Partnership | 6.89%5.54M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 5.87%4.72M shares |
STATE STREET CORP | 5.85%4.7M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.47%3.59M shares |
DIMENSIONAL FUND ADVISORS LP | 3.52%2.83M shares |
FIRST TRUST ADVISORS LP | 3.12%2.51M shares |
ARK Investment Management LLC | 2.86%2.3M shares |
WELLINGTON MANAGEMENT GROUP LLP | 2.83%2.27M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.62%2.1M shares |
GOLDMAN SACHS GROUP INC | 2.04%1.64M shares |
FULLER & THALER ASSET MANAGEMENT, INC. | 1.88%1.51M shares |
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.78%1.43M shares |
GW&K Investment Management, LLC | 1.76%1.42M shares |
MORGAN STANLEY | 1.48%1.19M shares |
BANK OF AMERICA CORP /DE/ | 1.37%1.1M shares |
Driehaus Capital Management LLC | 1.30%1.05M shares |
NORTHERN TRUST CORP | 1.24%996.15K shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.17%939.98K shares |
Percentages use 80.36M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 18, 2026Form 4 · 10b5-1 | EASTHAM KARINDirector | SellCommon Stock | 529 | $53.55 | $28.3K | 15.1K |
| Jun 18, 2026Form 4 · 10b5-1 | EASTHAM KARINDirector | SellCommon Stock | 3.2K | $52.78 | $168.9K | 15.6K |
| Jun 4, 2026Form 4 · 10b5-1 | Leite JohnGlobal Chief Commercial Off | SellCommon Stock | 14.0K | $50.07 | $699.7K | 132.3K |
| Jun 4, 2026Form 4 · 10b5-1 | McGuire AnnieEVP, General Counsel | SellCommon Stock | 1.8K | $50.12 | $89.0K | 137.2K |
| Jun 4, 2026Form 4 · 10b5-1 | McGuire AnnieEVP, General Counsel | SellCommon Stock | 1.4K | $49.31 | $69.0K | 139.0K |
Community posts
New Decipher analysis links genomic scores to benefit from added hormone therapy
Veracyte ($VCYT) reported a retrospective analysis of samples from 395 participants in a randomized Phase III prostate-cancer trial. Patients with intermediate or high Decipher genomic scores had an eight-percentage-point reduction in ten-y ...
